Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?

Por Hjardem, Elisabeth, Østergaard, Mikkel, Pødenphant, Jan, Tarp, Ulrik, Andersen, Lis Smedegaard, Bing, Jette, Peen, Elisabeth, Lindegaard, Hanne Merete, Ringsdal, Vibeke Stevenius, Rødgaard, Anne, Skøt, Jens, Hansen, Annette, Mogensen, Hans Henrik, Unkerskov, Janne, Hetland, Merete Lund
Publicado em 2007